backgroundmethod
longitudin
studi
respiratori
viru
infect
cumbersom
limit
understand
natur
histori
infect
solid
organ
transplant
sot
recipi
objectivesto
assess
feasibl
patient
accept
selfcollect
foam
nasal
swab
detect
respiratori
virus
sot
recipi
defin
virolog
clinic
cours
studi
designw
prospect
monitor
cours
symptomat
respiratori
viru
infect
sot
patient
lung
liver
kidney
use
patient
selfcollect
swab
initi
studi
sampl
posit
patient
follow
respiratori
virus
rhinoviru
metapneumoviru
coronaviru
respiratori
syncyti
viru
parainfluenza
viru
influenza
viru
one
hundr
four
weekli
selfcollect
nasal
swab
obtain
median
sampl
per
patient
rang
median
durat
viral
detect
day
rang
day
addit
new
respiratori
virus
detect
followup
patient
includ
rhinoviru
metapneumoviru
coronaviru
respiratori
syncyti
viru
parainfluenza
viru
adenoviru
specimen
collect
complianc
good
patient
collect
requir
specimen
followup
specimen
obtain
within
day
protocoldefin
window
particip
agre
strongli
agre
procedur
comfort
simpl
will
particip
futur
studi
use
procedur
conclusionselfcollect
nasal
swab
provid
conveni
feasibl
patientaccept
methodolog
longitudin
monitor
upper
respiratori
viru
infect
sot
recipi
respiratori
viru
infect
rvi
import
complic
solid
organ
transplant
patient
longitudin
virolog
cours
infect
extens
studi
part
logist
difficulti
obtain
repeat
providercollect
sequenti
specimen
understand
natur
histori
respiratori
viru
infect
popul
durat
viral
infect
viral
load
associ
symptom
import
design
futur
intervent
studi
assess
potenti
impact
rvi
pathogenesi
clinic
signific
outcom
transplant
acut
chronic
allograft
reject
secondari
bacteri
fungal
pulmonari
infect
selfcollect
nasal
swab
previous
shown
compar
sensit
providerobtain
specimen
use
monitor
rvi
immunocompet
subject
hematopoiet
cell
transplant
recipi
children
cystic
fibrosi
howev
studi
selfcollect
respiratori
sampl
obtain
clinic
observ
furthermor
previou
studi
assess
feasibl
accept
send
patient
selfcollect
specimen
use
commerci
avail
mail
system
prospect
longitudin
monitor
rvi
therefor
studi
design
address
least
part
limit
extend
work
previou
studi
purpos
present
studi
assess
feasibl
accept
sequenti
selfcollect
nasal
swab
longitudin
monitor
virolog
clinic
cours
upper
respiratori
tract
viral
infect
cohort
sot
patient
determin
potenti
util
cycl
threshold
ct
valu
obtain
sampl
assess
chang
viral
load
time
potenti
particip
identifi
realtim
databas
sot
recipi
laboratoryconfirm
respiratori
viru
infect
routin
clinic
care
univers
washington
medic
center
seattl
washington
written
inform
consent
particip
taught
selfcollect
procedur
research
coordin
assess
compet
demonstr
procedur
back
coordin
particip
provid
studi
kit
instruct
preaddressedprepaid
overnight
fedex
ship
mailer
fedex
inc
memphi
tn
instruct
collect
specimen
everi
day
two
consecut
specimen
neg
requir
two
neg
specimen
includ
ensur
posit
result
near
pcr
assay
threshold
miss
durat
viral
infect
episod
defin
amount
time
date
clinic
diagnosi
laboratoryconfirm
date
first
two
consecut
neg
studi
swab
pcr
result
new
episod
defin
detect
new
viral
pathogen
differ
initi
viru
patient
serial
monitor
studi
kit
previous
describ
use
steril
polyurethan
foam
swab
customshap
tip
puritan
medic
product
co
llc
arrow
particip
sent
swab
ambient
temperatur
steril
centrifug
tube
bio
express
inc
kaysvil
ut
particip
complet
survey
toler
procedur
symptom
survey
time
specimen
collect
symptom
survey
use
gener
weekli
symptom
score
patient
base
presenc
common
upper
respiratori
associ
system
symptom
specif
upper
respiratori
symptom
assess
rhinorrhea
sinu
congest
postnas
drip
short
breath
cough
wheezingchest
tight
sputum
sore
throat
sneez
wateri
eye
ear
ach
hoars
system
symptom
includ
subject
fever
headach
muscl
ach
diarrhea
total
symptom
score
sum
report
symptom
weekli
symptom
survey
maximum
possibl
score
studi
staff
either
schedul
weekli
pickup
patient
home
fedex
particip
deliv
mailer
fedex
ship
drop
box
receiv
central
pcr
laboratori
specimen
process
within
hour
test
use
real
time
pcr
assay
previous
describ
sampl
consid
posit
pcr
amplif
plot
cross
threshold
less
cycl
cycl
threshold
ct
qualiti
specimen
assess
amplif
human
betaglobin
dna
forward
primer
tgaaggctcatggcaagaaa
probe
tccaggtgagccaggccatca
cta
revers
primer
gctcactcagtgtggcaaagg
use
nucleic
acid
extract
sampl
previous
test
rvi
fred
hutchinson
cancer
research
center
institut
review
board
approv
studi
eighteen
sot
patient
enrol
lung
liver
kidney
transplant
recipi
median
age
year
mean
rang
includ
women
men
median
time
transplant
year
mean
year
rang
year
specimen
sent
locat
rang
mile
transplant
center
transit
time
selfcollect
sampl
arriv
laboratori
avail
followup
sampl
median
hour
rang
hour
sampl
rate
respiratori
viru
posit
differ
swab
whose
transit
time
less
hour
transit
time
greater
hour
specimen
detect
betaglobin
dna
rang
ul
specimen
median
correl
sampl
posit
rv
amount
betaglobin
present
measur
pcr
ct
ul
sampl
figur
betaglobin
mean
log
ul
specimen
rv
posit
sampl
similar
neg
sampl
particip
clinicallyord
laboratoryconfirm
upper
lower
rvi
either
cultur
pcr
either
bronchoalveolar
lavag
nasopharyng
swab
nasal
wash
total
sequenti
selfcollect
respiratori
sampl
obtain
particip
median
number
sampl
collect
per
particip
mean
rang
initi
studi
swab
neg
patient
patient
therefor
includ
longitudin
monitor
six
patient
one
posit
studi
swab
initi
swab
patient
second
viral
episod
new
viru
detect
monitor
initi
viral
infect
median
time
initi
posit
clinic
test
enrol
day
mean
rang
day
twentyfour
rvi
episod
identifi
patient
common
respiratori
viru
rhinoviru
follow
respiratori
syncyti
viru
human
coronavirus
parainfluenza
virus
human
metapneumoviru
tabl
patient
one
rvi
episod
rvi
list
separ
tabl
order
occur
posttransplant
eg
three
separ
rvi
episod
first
rhinoviru
infect
resolv
day
adenoviru
infect
last
least
day
patient
lost
followup
lastli
second
rhinoviru
episod
distinct
first
last
least
day
lost
followup
tabl
also
show
number
day
date
clinic
diagnosi
date
first
selfcollect
specimen
viru
mean
baselin
symptom
score
median
rang
among
particip
initi
diagnos
lower
tract
infect
bronchoalveolar
lavag
bal
viru
concomitantli
detect
upper
respiratori
tract
patient
selfcollect
specimen
tabl
document
viral
episod
last
least
day
patient
follow
least
two
week
interestingli
patient
new
respiratori
virus
detect
followup
monitor
ie
new
viru
identifi
specimen
sequenti
monitor
differ
initi
viral
episod
virolog
cours
new
viral
episod
ie
viral
detect
new
viru
patient
prior
viral
episod
shown
separ
supplement
figur
patient
abl
identifi
onset
infect
sinc
previou
monitor
new
viru
neg
overal
initi
secondari
viral
episod
sequenti
increas
ct
valu
time
indic
reduct
viral
load
cours
infect
figur
show
averag
chang
baselin
patientreport
symptom
score
initi
viral
episod
time
appar
increas
symptom
score
four
week
correspond
onset
symptomat
secondari
viral
episod
subset
studi
popul
seventynin
followup
specimen
collect
particip
within
protocoldefin
window
period
day
sampl
sixteen
particip
collect
protocolspecifi
sampl
studi
particip
complet
survey
agre
strongli
agre
procedur
comfort
simpl
messi
thirteen
particip
agre
strongli
agre
instruct
easi
follow
express
interest
particip
futur
studi
use
method
appli
simpl
patientaccept
feasibl
selfcollect
method
facilit
longitudin
monitor
upper
rvi
use
sensit
method
confirm
result
prior
studi
use
providercollect
swab
demonstr
durat
viral
shed
vari
substanti
prolong
studi
durat
viral
infect
initi
clinicallyobtain
posit
test
greater
week
major
patient
follow
least
two
week
high
rate
concomitantli
posit
nasal
swab
sampl
associ
posit
lower
respiratori
tract
sampl
consist
hypothesi
major
lower
tract
infect
repres
progress
infect
upper
respiratori
tract
thu
use
selfcollect
methodolog
could
use
understand
pathogenesi
progress
upper
lower
tract
infect
sinc
would
allow
determin
precis
time
upper
tract
infect
relat
lower
tract
diseas
howev
presenc
lower
tract
infect
without
concomit
upper
tract
infect
report
influenza
virus
might
relat
sensit
sampl
issu
although
methodolog
use
present
studi
quantit
ct
valu
rtpcr
assay
might
provid
estim
viral
load
infect
sequenti
ct
valu
show
pattern
increas
time
figur
supplement
figur
consist
sequenti
decreas
viral
load
furthermor
increas
ct
valu
concomitantli
associ
reduct
averag
patientreport
symptom
burden
figur
pcr
ct
valu
obtain
test
standard
selfcollect
specimen
describ
present
studi
could
potenti
use
gener
indic
viral
load
chang
time
futur
studi
systemat
assess
variabl
ct
valu
use
methodolog
confirm
observ
chang
ct
valu
greater
explain
specimen
collect
assay
variabl
furthermor
would
interest
determin
whether
chang
ct
valu
reliabl
associ
resolut
clinic
symptom
verifi
larger
studi
use
semiquantit
respiratori
viru
load
describ
methodolog
could
potenti
provid
patientaccept
use
mean
assess
respons
therapi
new
antivir
agent
reduct
immunosuppress
sever
interest
unexpect
find
studi
like
result
abil
methodolog
facilit
frequent
longitudin
monitor
cohort
immunosuppress
patient
risk
acquir
rvi
first
detect
addit
respiratori
virus
ie
new
viral
episod
patient
cours
monitor
initi
rvi
major
new
viral
episod
asymptomat
symptom
survey
lung
transplant
recipi
high
level
asymptomat
infect
consist
find
bridevaux
et
al
suggest
asymptomat
rvi
rel
common
lung
transplant
recipi
furthermor
asymptomat
symptomat
rvi
hypothes
contribut
persist
lung
injuri
possibl
long
term
chronic
lung
allograft
dysfunct
remain
determin
whether
subclin
infect
carri
similar
risk
symptomat
infect
posttranspl
complic
develop
bronchiol
obliteran
syndrom
restrict
allograft
syndrom
futur
prospect
studi
use
methodolog
describ
need
clarifi
import
issu
interestingli
found
appar
increas
durat
rhinoviru
infect
compar
respiratori
infect
tabl
could
relat
specif
host
viral
factor
given
small
number
find
interpret
cautious
futur
larger
studi
verifi
preliminari
interest
find
includ
specif
assess
possibl
mechan
sever
strength
present
studi
use
prospect
studi
design
set
highli
sensit
previous
wellvalid
pcr
assay
high
complianc
rate
monitor
one
limit
rel
small
number
patient
assess
generaliz
find
confirm
popul
sinc
studi
includ
select
patient
cognit
physic
capabl
perform
selfcollect
procedur
approach
might
applic
ill
patient
signific
cognit
physic
impair
addit
due
experi
patient
difficulti
collect
throat
swab
concern
adher
accept
eg
gag
choke
oralthroat
swab
studi
focus
nasal
swab
selfcollect
may
underdetect
virus
easier
isol
throat
swab
adenoviru
summari
describ
applic
patient
selfcollect
method
combin
sensit
rtpcr
longitudin
monitor
upper
respiratori
viral
infect
solid
organ
transplant
recipi
extend
result
previou
studi
includ
prospect
weekli
monitor
use
patient
selfcollect
nasal
swab
sent
central
lab
use
commerciallyavail
overnight
ambient
temperatur
ship
protocol
demonstr
feasibl
conveni
patientaccept
methodolog
longitudin
monitor
rvi
sot
patient
knowledg
pcr
ct
valu
specimen
collect
time
use
futur
natur
histori
intervent
studi
monitor
virolog
cours
rvi
immunosuppress
patient
popul
methodolog
could
also
potenti
use
facilit
selftest
diagnosi
upper
rvi
immunosuppress
patient
without
readi
access
medic
facil
evalu
selfcollect
nasal
swab
use
longitudin
studi
design
selfcollect
nasal
swab
feasibl
solid
organ
transplant
recipi
selfcollect
nasal
swab
accept
solid
organ
transplant
recipi
selfcollect
nasal
swab
conveni
longitudin
studi
respiratori
virus
initi
secondari
viral
episod
two
patient
footnot
neg
sampl
assign
ct
valu
assay
threshold
detect
averag
chang
symptom
score
baselin
footnot
weekli
sampl
collect
within
specifi
day
window
initi
viral
patient
studi
sampl
includ
c
patient
lost
follow
